Results 141 to 150 of about 21,376,824 (184)

Oral Administration of [¹⁸F]MC225 for Quantification of P-glycoprotein Function: A Feasibility Study. [PDF]

Mol Imaging Biol
Salvi de Souza G, Furini CRG, Sijbesma JWA, Kominia M, Doorduin J, Giacobbo BL, Lammertsma AA, Tsoumpas C, Luurtsema G.   +8 more
europepmc   +1 more source

Myosin Vb Traffics P-Glycoprotein to the Apical Membrane of Intestinal Epithelial Cells. [PDF]

Gastroenterology
Dooley SA, Kolobova E, Burman A, Kaji I, Digrazia JR, Stubler R, Goldstein A, Packirisamy C, Coutts AW, Saqui-Salces M, Gao N, Engevik MA, Shub MD, Goldenring JR, Engevik AC.   +14 more
europepmc   +1 more source

A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs. [PDF]

Clin Pharmacokinet
Coumau C, Csajka C.
europepmc   +1 more source

Serum p-Glycoprotein and Monomeric C-Reactive Protein are Elevated in Takayasu Arteritis. [PDF]

J Inflamm Res
Thakare DR, Singh K, Qamar T, Singh D, Balakrishnan S, Rathore U, Jain N, Ora M, Misra DP.   +8 more
europepmc   +1 more source

Cryo-EM of human P-glycoprotein reveals an intermediate occluded conformation during active drug transport. [PDF]

Nat Commun
Culbertson AT, Liao M.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Original Vinca Derivatives: From P-Glycoprotein Substrates to P-Glycoprotein Inhibitors

Journal of Medicinal Chemistry, 2016
The first example of vinca derivatives 16-18 able to modulate P-glycoprotein (Pgp) efflux activity is reported. They were elaborated in two steps from vinorelbine 3 (VLN) by a modification of the velbenamine moiety. These compounds were able to decrease efficiently Pgp mediated influx and efflux of rhodamine-123 (Rho) and to restore the cytotoxicity of
Olga, Gherbovet, María Concepción, García Alvarez, Jérôme, Bignon, Fanny, Roussi   +3 more
openaire   +3 more sources

Chemical molecular‐based approach to overcome multidrug resistance in cancer by targeting P‐glycoprotein (P‐gp)

Medicinal research reviews (Print), 2020
Multidrug resistance (MDR) remains one of the major impediments for efficacious cancer chemotherapy. Increased efflux of multiple chemotherapeutic drugs by transmembrane ATP‐binding cassette (ABC) transporter superfamily is considered one of the primary ...
Hang Zhang, Haiwei Xu, C. Ashby, Y. Assaraf, Zhe-Sheng Chen, Hong-min Liu   +5 more
semanticscholar   +1 more source

Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update.

Drug resistance updates, 2020
The presence of multidrug resistance (MDR) in malignant tumors is one of the primary causes of treatment failure in cancer chemotherapy. The overexpression of the ATP binding cassette (ABC) transporter, P-glycoprotein (P-gp), which significantly ...
Jinyun Dong, Zuodong Qin, Wei-Dong Zhang, Gang Cheng, Assaraf G Yehuda, C. Ashby, Zhe-Sheng Chen, Xiang-dong Cheng, Jiangjiang Qin   +8 more
semanticscholar   +1 more source

P-glycoprotein homologues

1994
Multidrug resistance (MDR) is defined by the simultaneous acquisition of cellular resistance to a broad range of cytotoxic compounds bearing little or no structural and functional homologies [1–5]. MDR is caused in cultured cells in vitro [6–9] and in tumor cells in vivo [10–12] by the overexpression of P-glycoprotein (Pgp) (reviewed in [13]).
E, Buschman, P, Lepage, P, Gros
openaire   +2 more sources

Functional intracellular P‐glycoprotein

International Journal of Cancer, 1998
Efflux of chemotherapy drugs by P-glycoprotein (P-gp) at the plasma membrane is thought to be a major cause of cancer multidrug resistance. In this report, we show by flow cytometry that P-gp also concentrates large amounts of 2 different drugs, Hoechst 33342 and daunorubicin, within a cytoplasmic compartment of multidrug resistant CHRC5 cells.
A B, Shapiro, K, Fox, P, Lee, Y D, Yang, V, Ling   +4 more
openaire   +2 more sources